ilead’s research and development chief is stepping down after nearly three decades at the company, concluding a run in which he steered the development of pioneering blockbuster therapies for HIV and hepatitis C but more recently became the target of Wall Street ire amid Gilead’s struggles to find a third act.

Norbert Bischofberger will leave his post at the end of April but will stay with the company through July, Gilead (GILD) announced on Monday. The company did not give a reason for his departure, but the move offers Gilead a chance to freshen its uppermost ranks without shaking up its strategy.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.